Blockchain Registration Transaction Record

Oncotelic's Saran Saund to Keynote Drug Discovery Summit on AI

Oncotelic Therapeutics' Saran Saund to keynote 22nd Drug Discovery Strategic Summit, discussing AI-enabled drug discovery and the PDAOAI platform indexing 29 million abstracts.

The integration of AI into drug discovery holds the potential to significantly reduce the time and cost associated with bringing new therapies to market. Oncotelic’s PDAOAI platform, with its extensive indexing of scientific literature, could empower researchers to identify novel drug targets and repurpose existing compounds more efficiently. By making AI-powered research tools accessible to individual investigators, Oncotelic may democratize drug discovery, enabling smaller research teams and academic labs to compete with larger organizations. This could lead to a more diverse pipeline of therapeutic candidates, particularly for rare pediatric cancers and other unmet medical needs. As the industry increasingly relies on data-driven approaches, Oncotelic’s advancements could position it as a key player in the AI-enabled drug discovery space, potentially attracting partnerships and investment. For patients, this means faster access to innovative treatments, while investors may see long-term value in the company’s proprietary technology and strategic vision.